Verve Therapeutics
Biotechnology company
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.
Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.
Visit website: https://www.vervetx.com/
Details last updated 29-Jun-2020
People at Verve Therapeutics
Verve Therapeutics News
Single-dose gene-editing therapy offers permanent solution to high cholesterol levels
New Scientist - 14-Nov-2023
Early results show promise in eliminating the need for lifelong statins
Read more...Verve Therapeutics' gene editing therapy may cure heart attacks once and for all
Bloomberg - 06-May-2022
Trials underway to test the safety, but affordability and acceptance of gene therapy are major concerns
Read more...Gene editing lowered blood level cholesterol and triglycerides in monkeys
New York Times - 27-Jun-2020
Could prevent not only the complications but the heart disease per se in the future
Read more...